Global Tardive Dyskinesia Treatment Market 2024-2028

The tardive dyskinesia treatment market is forecasted to grow by USD 632.45 mn during 2023-2028, accelerating at a CAGR of 4.73% during the forecast period. The report on the tardive dyskinesia treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising cases of mental disorders, growing antipsychotic prescription, and huge unmet need for neurological disease treatments.

Market Scope
Base Year	2023
End Year	2028
Series Year	2024-2028
Growth Momentum	Accelerate
YOY 2024	4.22%
CAGR	4.73%
Incremental Value	$632.45mn

Technavio's tardive dyskinesia treatment market is segmented as below:

By End-user

Hospital pharmacy
Retail pharmacy
Online pharmacy

By Product

Austedo and lngrezza
Amantadine
Others

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the initiatives to spread awareness regarding treatment of tardive dyskinesia as one of the prime reasons driving the tardive dyskinesia treatment market growth during the next few years. Also, growing regulatory approval for treating tardive dyskinesia and increasing research funding by pharmaceutical companies will lead to sizable demand in the market.

The report on the tardive dyskinesia treatment market covers the following areas:

Tardive dyskinesia treatment market sizing
Tardive dyskinesia treatment market forecast
Tardive dyskinesia treatment market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading tardive dyskinesia treatment market vendors that include Abbott Laboratories, Actiza Pharmaceutical Pvt. Ltd., Alembic Pharmaceuticals Ltd., Aspire Pharma Ltd., Centaur Pharmaceuticals Pvt. Ltd., Cipla Ltd., Hetero Labs Ltd., Lannett Co. Inc., Luye Pharma Group Ltd., Neurocrine Biosciences Inc., Novartis AG, Psicofarma S. A. de C. V, Ryon pharma, Sawai Group Holdings Co. Ltd., Slate Run Pharmaceuticals LLC, Solco Healthcare, SOM Innovation Biotech S.A., SteriMax Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.. Also, the tardive dyskinesia treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR76758

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by End-user
Exhibit 06: Executive Summary - Chart on Market Segmentation by Product
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global tardive dyskinesia treatment market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global tardive dyskinesia treatment market 2018 - 2022 ($ million)
4.2 End-user Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - End-user Segment 2018 - 2022 ($ million)
4.3 Product Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Product Segment 2018 - 2022 ($ million)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by End-user

6.1 Market segments
Exhibit 30: Chart on End-user - Market share 2023-2028 (%)
Exhibit 31: Data Table on End-user - Market share 2023-2028 (%)
6.2 Comparison by End-user
Exhibit 32: Chart on Comparison by End-user
Exhibit 33: Data Table on Comparison by End-user
6.3 Hospital pharmacy - Market size and forecast 2023-2028
Exhibit 34: Chart on Hospital pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibit 35: Data Table on Hospital pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibit 36: Chart on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
6.4 Retail pharmacy - Market size and forecast 2023-2028
Exhibit 38: Chart on Retail pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibit 39: Data Table on Retail pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibit 40: Chart on Retail pharmacy - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Retail pharmacy - Year-over-year growth 2023-2028 (%)
6.5 Online pharmacy - Market size and forecast 2023-2028
Exhibit 42: Chart on Online pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibit 43: Data Table on Online pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibit 44: Chart on Online pharmacy - Year-over-year growth 2023-2028 (%)
Exhibit 45: Data Table on Online pharmacy - Year-over-year growth 2023-2028 (%)
6.6 Market opportunity by End-user
Exhibit 46: Market opportunity by End-user ($ million)
Exhibit 47: Data Table on Market opportunity by End-user ($ million)

7 Market Segmentation by Product

7.1 Market segments
Exhibit 48: Chart on Product - Market share 2023-2028 (%)
Exhibit 49: Data Table on Product - Market share 2023-2028 (%)
7.2 Comparison by Product
Exhibit 50: Chart on Comparison by Product
Exhibit 51: Data Table on Comparison by Product
7.3 Austedo and Ingrezza - Market size and forecast 2023-2028
Exhibit 52: Chart on Austedo and Ingrezza - Market size and forecast 2023-2028 ($ million)
Exhibit 53: Data Table on Austedo and Ingrezza - Market size and forecast 2023-2028 ($ million)
Exhibit 54: Chart on Austedo and Ingrezza - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on Austedo and Ingrezza - Year-over-year growth 2023-2028 (%)
7.4 Amantadine and others - Market size and forecast 2023-2028
Exhibit 56: Chart on Amantadine and others - Market size and forecast 2023-2028 ($ million)
Exhibit 57: Data Table on Amantadine and others - Market size and forecast 2023-2028 ($ million)
Exhibit 58: Chart on Amantadine and others - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Amantadine and others - Year-over-year growth 2023-2028 (%)
7.5 Market opportunity by Product
Exhibit 60: Market opportunity by Product ($ million)
Exhibit 61: Data Table on Market opportunity by Product ($ million)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 65: Chart on Geographic comparison
Exhibit 66: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 Germany - Market size and forecast 2023-2028
Exhibit 87: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 88: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 89: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.9 UK - Market size and forecast 2023-2028
Exhibit 91: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 92: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 93: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.10 China - Market size and forecast 2023-2028
Exhibit 95: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibit 96: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibit 97: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on China - Year-over-year growth 2023-2028 (%)
9.11 France - Market size and forecast 2023-2028
Exhibit 99: Chart on France - Market size and forecast 2023-2028 ($ million)
Exhibit 100: Data Table on France - Market size and forecast 2023-2028 ($ million)
Exhibit 101: Chart on France - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on France - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 103: Market opportunity By Geographical Landscape ($ million)
Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 105: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 107: Overview on factors of disruption
11.4 Industry risks
Exhibit 108: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 109: Vendors covered
12.2 Market positioning of vendors
Exhibit 110: Matrix on vendor position and classification
12.3 Abbott Laboratories
Exhibit 111: Abbott Laboratories - Overview
Exhibit 112: Abbott Laboratories - Business segments
Exhibit 113: Abbott Laboratories - Key news
Exhibit 114: Abbott Laboratories - Key offerings
Exhibit 115: Abbott Laboratories - Segment focus
12.4 Alembic Pharmaceuticals Ltd.
Exhibit 116: Alembic Pharmaceuticals Ltd. - Overview
Exhibit 117: Alembic Pharmaceuticals Ltd. - Product / Service
Exhibit 118: Alembic Pharmaceuticals Ltd. - Key offerings
12.5 Aspire Pharma Ltd.
Exhibit 119: Aspire Pharma Ltd. - Overview
Exhibit 120: Aspire Pharma Ltd. - Product / Service
Exhibit 121: Aspire Pharma Ltd. - Key offerings
12.6 Centaur Pharmaceuticals Pvt. Ltd.
Exhibit 122: Centaur Pharmaceuticals Pvt. Ltd. - Overview
Exhibit 123: Centaur Pharmaceuticals Pvt. Ltd. - Product / Service
Exhibit 124: Centaur Pharmaceuticals Pvt. Ltd. - Key offerings
12.7 Cipla Ltd.
Exhibit 125: Cipla Ltd. - Overview
Exhibit 126: Cipla Ltd. - Business segments
Exhibit 127: Cipla Ltd. - Key news
Exhibit 128: Cipla Ltd. - Key offerings
Exhibit 129: Cipla Ltd. - Segment focus
12.8 Lannett Co. Inc.
Exhibit 130: Lannett Co. Inc. - Overview
Exhibit 131: Lannett Co. Inc. - Product / Service
Exhibit 132: Lannett Co. Inc. - Key offerings
12.9 Luye Pharma Group Ltd.
Exhibit 133: Luye Pharma Group Ltd. - Overview
Exhibit 134: Luye Pharma Group Ltd. - Business segments
Exhibit 135: Luye Pharma Group Ltd. - Key offerings
Exhibit 136: Luye Pharma Group Ltd. - Segment focus
12.10 Neurocrine Biosciences Inc.
Exhibit 137: Neurocrine Biosciences Inc. - Overview
Exhibit 138: Neurocrine Biosciences Inc. - Product / Service
Exhibit 139: Neurocrine Biosciences Inc. - Key offerings
12.11 Novartis AG
Exhibit 140: Novartis AG - Overview
Exhibit 141: Novartis AG - Business segments
Exhibit 142: Novartis AG - Key offerings
Exhibit 143: Novartis AG - Segment focus
12.12 Psicofarma S. A. de C. V
Exhibit 144: Psicofarma S. A. de C. V - Overview
Exhibit 145: Psicofarma S. A. de C. V - Product / Service
Exhibit 146: Psicofarma S. A. de C. V - Key offerings
12.13 Sawai Group Holdings Co. Ltd.
Exhibit 147: Sawai Group Holdings Co. Ltd. - Overview
Exhibit 148: Sawai Group Holdings Co. Ltd. - Product / Service
Exhibit 149: Sawai Group Holdings Co. Ltd. - Key offerings
12.14 SOM Innovation Biotech S.A.
Exhibit 150: SOM Innovation Biotech S.A. - Overview
Exhibit 151: SOM Innovation Biotech S.A. - Product / Service
Exhibit 152: SOM Innovation Biotech S.A. - Key offerings
12.15 SteriMax Inc.
Exhibit 153: SteriMax Inc. - Overview
Exhibit 154: SteriMax Inc. - Product / Service
Exhibit 155: SteriMax Inc. - Key offerings
12.16 Sun Pharmaceutical Industries Ltd.
Exhibit 156: Sun Pharmaceutical Industries Ltd. - Overview
Exhibit 157: Sun Pharmaceutical Industries Ltd. - Product / Service
Exhibit 158: Sun Pharmaceutical Industries Ltd. - Key offerings
12.17 Teva Pharmaceutical Industries Ltd.
Exhibit 159: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 160: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 161: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 162: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 163: Teva Pharmaceutical Industries Ltd. - Segment focus

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 164: Inclusions checklist
Exhibit 165: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 166: Currency conversion rates for US$
13.4 Research methodology
Exhibit 167: Research methodology
Exhibit 168: Validation techniques employed for market sizing
Exhibit 169: Information sources
13.5 List of abbreviations
Exhibit 170: List of abbreviations